Monopar Therapeutics
MNPR · Pharmaceutical Preparations · 6.7M shares · +6%/yr ↑ shares · EDGAR filings ↗
Reference price $69.95 · est. market cap ~$469M — last insider purchase, 2025-12-26 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — oncology clinical, extremely cash-rich.
Strengths
- Liquidity — current ratio 51.4 (99.6th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC
- Strong balance sheetStrong balance sheet — $123M cash & investments
- Notable holderHeld by 4 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +1 more (as of 2026-03-31)
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-10.0%
Return on assets
-9.7%
Current ratio
51.4×
Tangible book value
$138M
Cash & investments
$123M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-31 | Robinson Chandler | Option exercise | 6.7K | — |
| 2026-03-31 | Robinson Chandler | Tax withheld | 2.0K | $54.79 |
| 2026-03-31 | Cittadine Andrew | Option exercise | 3.5K | — |
| 2026-03-31 | Cittadine Andrew | Tax withheld | 1.6K | $54.79 |
| 2025-12-31 | Cittadine Andrew | Tax withheld | 1.9K | $65.30 |
| 2025-12-31 | Robinson Chandler | Option exercise | 8.7K | — |
| 2025-12-31 | Robinson Chandler | Tax withheld | 2.6K | $65.30 |
| 2025-12-31 | Cittadine Andrew | Option exercise | 4.3K | — |
| 2025-12-26 | Vu Quan Anh | Buy | 1.5K | $69.95 |
| 2025-12-18 | KLAUSNER ARTHUR J | Sell | 4.7K | $67.06 |
| 2025-12-18 | KLAUSNER ARTHUR J | Sell | 461 | $68.09 |
| 2025-12-16 | Hendricks Diane | Other | 43K | — |
| 2025-12-16 | KLAUSNER ARTHUR J | Other | 7.7K | — |
| 2025-09-30 | Robinson Chandler | Tax withheld | 2.6K | $81.67 |
| 2025-09-30 | Cittadine Andrew | Option exercise | 4.3K | — |
| 2025-09-30 | Cittadine Andrew | Tax withheld | 1.9K | $81.67 |
| 2025-09-30 | Robinson Chandler | Option exercise | 8.7K | — |
| 2025-09-24 | Tactic Pharma LLC | Sell | 550K | $63.61 |
| 2025-07-14 | Tsuchimoto Kim R | Sell | 8.9K | $40.00 |
| 2025-07-14 | Tsuchimoto Kim R | Option exercise | 8.9K | $0.01 |
| 2025-07-14 | STARR CHRISTOPHER M | Option exercise | 17K | $0.01 |
| 2025-07-14 | STARR CHRISTOPHER M | Sell | 17K | $40.00 |
| 2025-07-14 | Robinson Chandler | Option exercise | 17K | $0.01 |
| 2025-07-14 | Robinson Chandler | Sell | 17K | $40.00 |
| 2025-06-30 | Robinson Chandler | Option exercise | 13K | — |
| 2025-06-30 | Robinson Chandler | Tax withheld | 5.9K | $35.78 |
| 2025-06-30 | Cittadine Andrew | Option exercise | 6.9K | — |
| 2025-06-30 | Cittadine Andrew | Tax withheld | 3.0K | $35.78 |
| 2025-04-02 | Tactic Pharma LLC | Sell | 33K | $35.00 |
| 2025-03-31 | Robinson Chandler | Option exercise | 4.1K | — |
| 2025-03-31 | Cittadine Andrew | Option exercise | 1.8K | — |
| 2025-03-31 | Cittadine Andrew | Tax withheld | 744 | $36.41 |
| 2025-03-31 | Robinson Chandler | Tax withheld | 1.2K | $36.41 |
| 2025-03-04 | Robinson Chandler | Tax withheld | 1.8K | $31.70 |
| 2025-03-04 | Robinson Chandler | Option exercise | 6.0K | — |
| 2025-01-28 | Robinson Chandler | Other | 63K | — |
| 2024-12-31 | Robinson Chandler | Option exercise | 4.9K | — |
| 2024-12-31 | Cittadine Andrew | Option exercise | 1.8K | — |
| 2024-12-31 | Cittadine Andrew | Tax withheld | 721 | $22.00 |
| 2024-12-31 | Robinson Chandler | Tax withheld | 2.2K | $22.00 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06617169 ↗ | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors Solid Tumor, Adult, Bladder Cancer | PHASE1 | Recruiting | 2026-12-01 |
| NCT06337084 ↗ | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors Solid Tumor, Adult, Bladder Cancer | PHASE1 | Recruiting | 2026-04-01 |
| NCT05043649 ↗ | Camsirubicin + Pegfilgrastim to Determine MTD in ASTS Advanced Soft-tissue Sarcoma | PHASE1 | Terminated | 2023-10-31 |
| NCT04648020 ↗ | Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. Chemoradiotherapy-Induced Severe Oral Mucositis | PHASE2/PHASE3 | Terminated | 2023-05-14 |
| NCT06980506 ↗ | MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer Cancer, Solid Tumor | — | Available | |
| NCT06980519 ↗ | MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer Cancer, Solid Tumor | — | Available |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-26 | 2026-06-26 | 0001437749-26-021832 ↗ |
| 8-K | 2026-06-23 | 2026-06-22 | 0001437749-26-021350 ↗ |
| 8-K | 2026-05-29 | 2026-05-29 | 0001437749-26-018896 ↗ |
| 8-K | 2026-05-19 | 2026-05-19 | 0001437749-26-017821 ↗ |
| 10-Q | 2026-05-14 | 2026-03-31 | 0001437749-26-016982 ↗ |
| 8-K | 2026-05-14 | 2026-05-14 | 0001437749-26-016981 ↗ |
| 8-K | 2026-04-20 | 2026-04-19 | 0001437749-26-012751 ↗ |
| 10-K/A | 2026-04-01 | 2025-12-31 | 0001437749-26-010841 ↗ |
| 10-K | 2026-03-27 | 2025-12-31 | 0001437749-26-010025 ↗ |
| 8-K | 2026-03-27 | 2026-03-27 | 0001437749-26-010030 ↗ |
| 8-K | 2026-03-02 | 2026-03-02 | 0001437749-26-006229 ↗ |
| 8-K | 2025-11-13 | 2025-11-13 | 0001437749-25-034618 ↗ |